Zevra Therapeutics heads into September with a striking divergence: short sellers have spent a month covering positions aggressively, while institutional investors are quietly building some of the largest stakes the register has seen.
The short covering story is the most compelling data point this week. Short interest has fallen roughly 22% over the past month, dropping from above 8 million shares in late July to around 6.1 million now — equivalent to 10.9% of the free float. That is still a meaningfully high level for a small-cap pharma, but the direction of travel is unambiguous. The borrow market tells a similar story. Availability has expanded dramatically over the same period, reaching 562% — meaning roughly five-and-a-half shares are available to lend for every one currently borrowed. A month ago that ratio was closer to three-to-one. Borrowing costs remain low at 0.42%, barely changed in real terms despite a modest week-on-week uptick. This is not a squeeze setup — it is a market where shorts are choosing to leave rather than being forced out.
Options positioning adds a nuanced layer. The put/call ratio has moved well below its 20-day average of 1.54, printing at 1.34 — nearly 1.5 standard deviations below that mean. Compared to readings above 1.70 in late July and early August, options traders have rotated away from defensive hedges. That shift mirrors the short covering: the more bearish voices in the market appear to be stepping back. The ORTEX short score of 55.5 sits in a modest middling range, having eased from a recent high of 56.5 a fortnight ago, consistent with the broader de-risking trend.
Institutional conviction deserves attention. FMR LLC raised its stake from 5.5% to 8.3% as of its August 6 filing. Woodline Partners lifted its position from 6.2% to 8.1%, per its August 14 disclosure. BlackRock holds 8.6% and added over 650,000 shares in the period ending July 31. These are not passive index flows — three separate active managers materially increasing positions simultaneously is a notable alignment. All 13D/G stakes are as last disclosed and holders dropping below 5% may exit without a further filing, but the direction of the most recent amendments is consistently upward.
The analyst community is broadly constructive, though targets compressed after a sharp drawdown in late July. Guggenheim and BTIG both lowered targets to the $23-24 range at that point, while Canaccord cut to $20. The subsequent recovery — the stock has climbed 27% over the past month to $12.06 — has prompted Citizens to raise its target to $28 and HC Wainwright to reiterate at $26. The mean target across the coverage group sits near $25, implying roughly 107% potential upside from current levels. The bull case rests on MIPLYFFA's commercial ramp in Niemann-Pick disease type C and the phase 3 programme in vascular Ehlers-Danlos syndrome. Bears point to the limited patient population, profitability timelines, and the capital requirements that rare-disease programmes typically demand. The P/E multiple has expanded about 27% over the past 30 days to roughly 11x, while EV/EBITDA near 8x has eased slightly — valuation is not stretched relative to peers, though the value factor score ranks near the bottom of the ORTEX universe.
The last earnings print, from August 5, generated a 13% single-day gain and held a further 9% advance over the subsequent five days — a meaningful positive reaction that helped catalyse the month's recovery. The next event is not until November 9, which leaves a long runway. What to watch between now and then: whether institutional buyers continue building around the $12 level, whether the short interest base — still nearly 11% of float — shows renewed selling pressure or keeps declining, and whether the options market's newfound calm holds as the pipeline data flow continues.
See the live data behind this article on ORTEX.
Open ZVRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
